NCT05469087

Brief Summary

CoHPT is a prospective, monocentric, observational cohort including all patients diagnosed with primary hyperparathyroidism in Nantes University Hospital, aiming to study the outcomes associated with parathyroidectomy. Clinical and biochemical evaluation is performed at the inclusion, and 6, 12, 36 and 60 months. A biocollection is collected. The main hypotheses are that parathyroidectomy could improve cardiovascular, renal, bone, and cardiovascular outcomes along with quality of life.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
403

participants targeted

Target at P75+ for all trials

Timeline
10mo left

Started Mar 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Mar 2016Feb 2027

Study Start

First participant enrolled

March 31, 2016

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 24, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 7, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

July 21, 2022

Completed
4.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 24, 2027

Expected
Last Updated

September 8, 2025

Status Verified

August 1, 2025

Enrollment Period

5.9 years

First QC Date

July 7, 2022

Last Update Submit

August 29, 2025

Conditions

Keywords

Primary hyperparathyroidismParathyroidectomy

Outcome Measures

Primary Outcomes (7)

  • Occurrence of cardiovascular events, after parathyroidectomy for primary hyperparathyroidism

    Cardiovascular events include myocardial infarction, cerebrovascular and peripheral arterial events

    Between inclusion and 12 months after surgery

  • Change in LDL-cholesterol concentration after surgery

    Plasma LDL-cholesterol (mg/dL) will be directly measured using enzymatic method

    Between inclusion and 12 months after surgery

  • Change in HDL-cholesterol concentration after surgery

    Plasma HDL-cholesterol (mg/dL) will be measured using enzymatic method

    Between inclusion and 12 months after surgery

  • Change in plasma triglycerides concentration after surgery

    Plasma triglycerides (mg/dL) will be measured using enzymatic method

    Between inclusion and 12 months after surgery

  • Change in homeostasis model assessment HOMA-IR index after surgery

    HOMA-IR is calculated using fasting plasma glucose and insulin level, with the following formula: (fasting plasma insulin (mIU/L) × fasting plasma glucose (mmol/L))/22.5

    Between inclusion and 12 months after surgery

  • Change in homeostasis model assessment HOMA-B index after surgery

    HOMA-B is calculated using fasting plasma glucose and insulin level, with the following formula: 20 × fasting plasma insulin (mIU/L)/\[fasting plasma glucose (mmol/L) - 3.5\]

    Between inclusion and 12 months after surgery

  • Change in arterial stiffness after surgery

    Arterial stiffness is reflected by the measurement of the pulse wave velocity using the PoPmeter® instrument

    Between inclusion and 12 months after surgery

Secondary Outcomes (21)

  • Occurrence of cardiovascular events, after parathyroidectomy for primary hyperparathyroidism

    Between inclusion and 60 months after surgery

  • Change in LDL-cholesterol concentration after surgery

    Between inclusion and 60 months after surgery

  • Change in HDL-cholesterol concentration after surgery

    Between inclusion and 60 months after surgery

  • Change in plasma triglycerides concentration after surgery

    Between inclusion and 60 months after surgery

  • Change in homeostasis model assessment HOMA-IR index after surgery

    Between inclusion and 60 months after surgery

  • +16 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All consecutive patients consulting for sporadic primary hyperparathyroidism in Nantes University Hospital

You may qualify if:

  • Age \> 18

You may not qualify if:

  • Age \< 18
  • Pregnancy / lactation
  • Adults underguardianship
  • Secondary/tertiary hyperparathyroidism
  • Multiple endocrine neoplasia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

RECRUITING

Related Publications (2)

  • Loison M, Wargny M, Caillard C, Guillot P, Le Bras M, Cariou B, Blanchard C, Mirallie E, Frey S. Radius Bone Mineral Density Measurement Is Essential During Initial PHPT Workup: Results of a Retrospective Study on 400 Patients. World J Surg. 2026 Jan 4. doi: 10.1002/wjs.70223. Online ahead of print.

  • Frey S, Perrot B, Caillard C, Le Bras M, Gerard M, Blanchard C, Cariou B, Wargny M, Mirallie E. Parathyroidectomy for primary hyperparathyroidism: effect on quality of life after 3 years - a prospective cohort study. Int J Surg. 2023 Mar 1;109(3):364-373. doi: 10.1097/JS9.0000000000000282.

MeSH Terms

Conditions

Hyperparathyroidism, Primary

Condition Hierarchy (Ancestors)

HyperparathyroidismParathyroid DiseasesEndocrine System Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 7, 2022

First Posted

July 21, 2022

Study Start

March 31, 2016

Primary Completion

February 24, 2022

Study Completion (Estimated)

February 24, 2027

Last Updated

September 8, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations